Literature DB >> 21259378

Long-term use of zopiclone, zolpidem and zaleplon among Danish elderly and the association with sociodemographic factors and use of other drugs.

Ane Birgitte Telén Andersen1, Morten Frydenberg.   

Abstract

PURPOSE: To estimate the degree of long-term use of zopiclone, zolpidem and zaleplon among Danes aged 65 and older and the association with sociodemographic factors and use of other drugs.
METHODS: Danish register-based study of 5000 men and 5000 women aged 65 or older on 1 January 2004. Information on sociodemographic factors and drug redemptions were collected for 2003, with follow-up of zopiclone, zolpidem and zaleplon redemptions in 2004. Long-term use was defined as redemptions corresponding to a continuous daily use for more than 4 weeks (based on ½ DDD). The association between long-term use and sociodemographics and drug use was estimated by logistic regression.
RESULTS: Ten per cent of all men and 16% of all women had a long-term use for minimum 4 weeks corresponding to 94% of the male and 93% of the female users. Four per cent of the men and 6% of the women had redeemed more than ½ DDD per day in 2004. Long-term use was associated with: Being a woman, high age, widowed or divorced, high education and high gross income. Long-term use was also associated with use of other drugs, the association with ATC group N being the strongest. Restricting the analyses to individuals who had minimum one zopiclone, zolpidem or zaleplon redemption gave similar results.
CONCLUSION: The results indicate that the guidance for length of use is not followed. Long-term use of zopiclone, zolpidem and zaleplon is associated with sociodemographic factors and use of other drugs, particularly from ATC group N.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21259378     DOI: 10.1002/pds.2104

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  12 in total

1.  Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors: a population-based study.

Authors:  Arnaud Panes; Antoine Pariente; Anne Bénard-Laribière; Régis Lassalle; Caroline Dureau-Pournin; Simon Lorrain; Marie Tournier; Annie Fourrier-Réglat
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-12-11       Impact factor: 5.270

2.  Long-term use of benzodiazepines in older patients in Germany: a retrospective analysis.

Authors:  Louis Jacob; Michael A Rapp; Karel Kostev
Journal:  Ther Adv Psychopharmacol       Date:  2017-03-01

3.  Relationship of zolpidem and cancer risk: a Taiwanese population-based cohort study.

Authors:  Chia-Hung Kao; Li-Min Sun; Ji-An Liang; Shih-Ni Chang; Fung-Chang Sung; Chih-Hsin Muo
Journal:  Mayo Clin Proc       Date:  2012-05       Impact factor: 7.616

4.  Trends in benzodiazepine receptor agonists use and associated factors in the Belgian general older population: analysis of the Belgian health interview survey data.

Authors:  Catherine Pétein; Anne Spinewine; Séverine Henrard
Journal:  Ther Adv Psychopharmacol       Date:  2021-05-25

5.  Benefits and risks of benzodiazepines and Z-drugs: comparison of perceptions of GPs and community pharmacists in Germany.

Authors:  Falk Hoffmann
Journal:  Ger Med Sci       Date:  2013-07-18

6.  Factors associated with alcohol consumption and prescribed drugs with addiction potential among older women and men - the Nord-Trøndelag health study (HUNT2 and HUNT3), Norway, a population-based longitudinal study.

Authors:  Kjerstin Tevik; Geir Selbæk; Knut Engedal; Arnfinn Seim; Steinar Krokstad; Anne-S Helvik
Journal:  BMC Geriatr       Date:  2019-04-18       Impact factor: 3.921

7.  Long-term benzodiazepines and z-drug prescribing in Australian general practice between 2011 and 2018: A national study.

Authors:  Amelia Woods; Mumtaz Begum; David Gonzalez-Chica; Carla Bernardo; Elizabeth Hoon; Nigel Stocks
Journal:  Pharmacol Res Perspect       Date:  2022-02

Review 8.  Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness.

Authors:  Joseph V Pergolizzi; Robert Taylor; Robert B Raffa; Srinivas Nalamachu; Maninder Chopra
Journal:  Sleep Disord       Date:  2014-02-05

9.  What is Behind the Seeming Cessation of the Increase in Sleep Medicine Consumption in Finland During the Last Years?

Authors:  Erkki Kronholm; Juha Markkula; Lauri J Virta
Journal:  J Public Health Res       Date:  2012-06-12

10.  Risk of long-term benzodiazepine and Z-drug use following the first prescription among community-dwelling adults with anxiety/mood and sleep disorders: a retrospective cohort study.

Authors:  Jaden Brandt; Donica Janzen; Silvia Alessi-Severini; Alexander Singer; Dan Chateau; Murray Enns; Christine Leong
Journal:  BMJ Open       Date:  2021-11-01       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.